Sovaldi (sofosbuvir) likely will maintain its market-leading presence, but abstracts for EASL presentations show that AbbVie's late-stage therapies and Merck's mid-stage compounds also are capable of performing well in patients with the hepatitis C virus…
written on 25.03.2014